Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study)

Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists

(2012) Tae Woo Kim et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension

(2012) Sang Eun Lee et al.   CLINICAL THERAPEUTICS

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

(2011) William B. White et al.   HYPERTENSION

Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers

(2011) SoJeong Yi et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring

(2011) Domenic Sica et al.   Journal of Clinical Hypertension

Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry

(2011) Dong-Ju Choi et al.   Korean Circulation Journal

Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis

(2010) Bret R. Haymore et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

(2009) T. Sawada et al.   EUROPEAN HEART JOURNAL

Thrombolytics for PE and right ventricular dysfunction

(2008) Syed Wamique Yusuf et al.   LANCET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE